Can-Fite BioPharma (NYSE:CANF) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

Separately, StockNews.com began coverage on Can-Fite BioPharma in a research report on Saturday. They issued a “sell” rating on the stock.

Can-Fite BioPharma Price Performance

CANF stock opened at $2.02 on Tuesday. The firm has a market capitalization of $7.15 million, a P/E ratio of -1.13 and a beta of 1.12. The business’s 50-day moving average is $1.59 and its two-hundred day moving average is $1.88. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.